Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct 9:jiaf519.
doi: 10.1093/infdis/jiaf519. Online ahead of print.

Trichomonas vaginalis Among Cisgender Women Taking Doxycycline Postexposure Prophylaxis

Fredericka Albertina Sesay  1 , Kevin Oware  2 , Lauren R Violette  3   4   5 , Deborah Donnell  6 , Josephine B Odoyo  2 , Victor Omollo  2 , Felix O Mogaka  2 , R Scott McClelland  1   3   7 , Jennifer E Balkus  1   8 , Elizabeth A Bukusi  7   9   2 , Jared M Baeten  3   7 , Jenell Stewart  10   11
Affiliations

Trichomonas vaginalis Among Cisgender Women Taking Doxycycline Postexposure Prophylaxis

Fredericka Albertina Sesay et al. J Infect Dis. .

Abstract

Doxycycline treats and prevents several bacterial and parasitic infections and has been proposed as a possible treatment for Trichomonas vaginalis. Nested in a trial of doxycycline postexposure prophylaxis among cisgender women in Kenya, we conducted a secondary analysis of incident T. vaginalis infections. Among 224 cisgender women randomized to doxycycline postexposure prophylaxis and 225 to standard-of-care, there were 27 T. vaginalis diagnoses in the doxycycline postexposure prophylaxis group and 29 in the standard-of-care group (RR: 0.96, 95% CI: 0.54-1.73, p=0.9)). Understanding doxycycline postexposure prophylaxis's impact on T. vaginalis remains an important public health question that warrants further investigation.

Keywords: Trichomonas vaginalis; DoxyPEP; Doxycycline; Prevention; Women.

PubMed Disclaimer

LinkOut - more resources